For example, peptide p28 is a post-translational, multi-target anticancer agent that preferentially enters a wide variety of solid tumor cells and binds to both wild-type and mutant p53 protein, inhibiting constitutional morphogenic protein 1 (Cop1)-mediated ubiquitination and proteasomal degradation of p53, which results in increased levels of p53 and induces cell-cycle arrest at G2/M and eventual apoptosis, which results in tumor cell shrinkage and death [4]. The gene discussed is TP53; the disease is neoplasm.